Product Description
For Renal Anemia; UB-851 (rhEPO) has been developed as a biosimilar product to Eprex¨. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02708914)
Mechanisms of Action: ERA Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: UBI Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02708914 |
P304-EPO | P3 |
Completed |
Anemia |
2021-10-01 |
2023-12-07 |
Recent News Events
Date |
Type |
Title |
|---|